Drug Profile
Research programme: siRNA therapeutics - Abeona Therapeutics/undisclosed company
Latest Information Update: 24 May 2018
Price :
$50
*
At a glance
- Originator Access Pharmaceuticals; Unknown
- Developer Abeona Therapeutics; Unknown
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 24 May 2018 Discontinued - Preclinical for Undefined indication in USA (IV)
- 24 May 2018 Discontinued for Undefined indication in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (PO)